Skip to: top navigation | main navigation | main content

Date 5 December 2018
Title In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform (US time zone)
Organiser SenzaGen AB
Location Webinar

The presentation will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics. A thorough explanation of the GARD platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARDTM is based on functional genomics.

The presentation will cover:

  • Development of the genomic-based GARD test platform for skin sensitization hazard, potency classification, and now also respiratory sensitization.

  • Dendritic cells – why they are also relevant for respiratory sensitization.

  • Gene mapping – what genes are in the assay, and how are they relevant for sensitization.

  • How GARD can discriminate between skin and respiratory sensitization and why this is relevant.

  • Update on the development of the SenzaGen R&D pipeline including GARD for materials – testing medical devices, GARD for proteins – classification of protein sensitizers, GARD for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.

Registration URL:
Webinar ID: 831-861-723

Further Information